186.3K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 763,829 | 763,829 | - | - | Stock Option (Right to Buy) | |
| Donald Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Julia D. Maltzman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 750,000 | 750,000 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 24 Jan 2025 | 28,101 | 137,201 | - | 0.9 | 25,904 | Common Stock |
| Donald Healey | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 24 Jan 2025 | 8,560 | 63,769 | - | 0.9 | 7,891 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 24 Jan 2025 | 6,270 | 56,241 | - | 0.9 | 5,780 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 37,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 70,200 | 0 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 70,200 | 70,200 | - | - | Stock Option (Right to Buy) | |
| Lloyd Klickstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 70,200 | 70,200 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 11,800 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 1,770,427 | 1,770,427 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 11,800 | - | 0 | Common Stock | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 1.43 per share. | 05 Jun 2024 | 5,900 | 5,900 | - | 1.4 | 8,437 | Common Stock |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 16,800 | - | 0 | Common Stock | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 11,800 | - | 0 | Common Stock | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 11,800 | - | 0 | Common Stock | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Donald Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 271,595 | 271,595 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 375,077 | 375,077 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 336,911 | 336,911 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 5,900 | - | 0 | Common Stock | |
| L. Gordon Carl | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.40 per share. | 25 Jan 2024 | 1,841,100 | 7,526,359 | - | 2.4 | 4,418,640 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.40 per share. | 25 Jan 2024 | 242,200 | 990,254 | - | 2.4 | 581,280 | Common Stock |
| Gordon L. Carl | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.40 per share. | 25 Jan 2024 | 1,041,700 | 1,255,985 | - | 2.4 | 2,500,080 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 241,173 | 241,173 | - | - | Stock Option (Right to Buy) | |
| Schor Chen | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 1,116,903 | 1,116,903 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 19,700 | 72,329 | - | 0 | Common Stock | |
| Schor Chen | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 70,300 | 208,771 | - | 0 | Common Stock | |
| Healey Don | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 24 Jan 2024 | 4,870 | 52,629 | - | 2.4 | 11,688 | Common Stock |
| Galimi Francesco | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 26,300 | 101,801 | - | 0 | Common Stock | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 19,700 | 62,511 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 24 Jan 2024 | 15,290 | 138,471 | - | 2.4 | 36,696 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 288,134 | 288,134 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 24 Jan 2024 | 3,565 | 42,811 | - | 2.4 | 8,556 | Common Stock |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 211,633 | 211,633 | - | - | Stock Option (Right to Buy) | |
| Galimi Francesco | SVP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 24 Jan 2024 | 4,957 | 75,501 | - | 2.4 | 11,897 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Carl L. Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 240,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 872,111 | 872,111 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 872,111 | 0 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 36,857 | 36,857 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 36,857 | 0 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 384,900 | 384,900 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 384,900 | 0 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 295,000 | 295,000 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 295,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 421,600 | 421,600 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 421,600 | 0 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 37,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 125,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 30,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 70,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 117,200 | 117,200 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 149,944 | 149,944 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 117,200 | 0 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 30,400 | 30,400 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 1,172 | 1,172 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 1,172 | 0 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 28,828 | 0 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 28,828 | 28,828 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 77,269 | 77,269 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 113,652 | 0 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 113,652 | 113,652 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 77,269 | 0 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 73,964 | 0 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 73,964 | 73,964 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,625 | 0 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,625 | 26,625 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 125,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 117,200 | 0 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 117,200 | 117,200 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 56,612 | 0 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 56,612 | 56,612 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 125,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 117,200 | 117,200 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 117,200 | 0 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 70,200 | 0 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 70,200 | 70,200 | - | - | Stock Option (Right to Buy) | |
| Katie Peng | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2023 | 70,200 | 70,200 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Purchase of securities on an exchange or from another person at price $ 2.40 per share. | 30 Jun 2023 | 5,000 | 10,900 | - | 2.4 | 12,000 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.09 per share. | 27 Jun 2023 | 442,000 | 5,685,259 | - | 2.1 | 923,780 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.09 per share. | 27 Jun 2023 | 250,000 | 646,657 | - | 2.1 | 522,500 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.09 per share. | 27 Jun 2023 | 125,000 | 1,027,885 | - | 2.1 | 261,250 | Common Stock |
| Carl L. Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.09 per share. | 27 Jun 2023 | 58,000 | 748,054 | - | 2.1 | 121,220 | Common Stock |
| Carl L. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Carl L. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Don Healey | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 7.57 per share. | 15 Feb 2023 | 4,533 | 66,568 | - | 7.6 | 34,327 | Common Stock |
| Don Healey | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 7.98 per share. | 10 Feb 2023 | 10,467 | 71,101 | - | 8.0 | 83,476 | Common Stock |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 85,500 | 176,969 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 384,900 | 384,900 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 117,200 | 117,200 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 26,100 | 81,568 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 26,100 | 88,551 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 117,200 | 117,200 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 117,200 | 117,200 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 26,100 | 54,309 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 64,757 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 9,955 | 48,000 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 9,955 | 43,469 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 53,424 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 38,045 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 26,712 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 64,757 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 91,469 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 0 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 26,712 | 26,712 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 21.03 per share. | 10 Nov 2022 | 9,955 | 91,469 | - | 21.0 | 209,322 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 20.06 per share. | 10 Nov 2022 | 30,000 | 53,424 | - | 20.1 | 601,920 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 10 Nov 2022 | 6,967 | 28,209 | - | 21 | 146,307 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 19.05 per share. | 07 Nov 2022 | 30,000 | 83,424 | - | 19.0 | 571,488 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 02 Nov 2022 | 500 | 138,237 | - | 18 | 9,000 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 02 Nov 2022 | 24,813 | 113,424 | - | 18.0 | 447,718 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.27 per share. | 19 Oct 2022 | 8,067 | 35,176 | - | 16.3 | 131,250 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.40 per share. | 12 Oct 2022 | 1,646 | 51,176 | - | 15.4 | 25,348 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2022 | 3,388 | 56,612 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.92 per share. | 12 Oct 2022 | 7,933 | 43,243 | - | 15.9 | 126,293 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.38 per share. | 12 Oct 2022 | 3,388 | 52,822 | - | 7.4 | 25,003 | Common Stock |
| Chen Schor | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.22 per share. | 04 Oct 2022 | 21,288 | 101,424 | - | 14.2 | 302,715 | Common Stock |
| Don Healey | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.22 per share. | 04 Oct 2022 | 7,933 | 55,468 | - | 14.2 | 112,807 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.22 per share. | 04 Oct 2022 | 7,933 | 62,451 | - | 14.2 | 112,807 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 14 Sep 2022 | 952 | 138,737 | - | 18 | 17,136 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 09 Sep 2022 | 3,371 | 139,689 | - | 18.0 | 60,713 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 09 Sep 2022 | 200 | 143,060 | - | 18 | 3,600 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.77 per share. | 09 Sep 2022 | 66,747 | 0 | - | 16.8 | 1,119,307 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.51 per share. | 09 Sep 2022 | 8,094 | 66,747 | - | 16.5 | 133,601 | Common Stock |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Aug 2022 | 53,424 | 143,260 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2022 | 48,000 | 144,000 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Aug 2022 | 53,424 | 96,000 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.25 per share. | 04 Aug 2022 | 21,288 | 122,712 | - | 18.3 | 388,506 | Common Stock |
| Don Healey | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.25 per share. | 04 Aug 2022 | 5,533 | 63,401 | - | 18.2 | 100,977 | Common Stock |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2022 | 16,000 | 68,934 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.25 per share. | 04 Aug 2022 | 5,533 | 70,384 | - | 18.2 | 100,977 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2022 | 16,000 | 75,917 | - | 0 | Common Stock | |
| Blake Aftab | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.25 per share. | 04 Aug 2022 | 5,533 | 49,434 | - | 18.2 | 100,977 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2022 | 16,000 | 54,967 | - | 0 | Common Stock | |
| Blake Aftab | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 03 Aug 2022 | 6,968 | 38,967 | - | 18 | 125,424 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.64 per share. | 01 Aug 2022 | 6,968 | 45,935 | - | 16.6 | 115,948 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.50 per share. | 05 Jul 2022 | 1,363 | 52,903 | - | 14.5 | 19,764 | Common Stock |
| Carl L. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 01 Apr 2022 | 1,775 | 59,917 | - | 21 | 37,275 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.82 per share. | 01 Apr 2022 | 1,775 | 61,692 | - | 16.8 | 29,856 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 01 Apr 2022 | 168 | 59,917 | - | 21 | 3,528 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.97 per share. | 01 Apr 2022 | 168 | 60,085 | - | 6.0 | 1,003 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 01 Apr 2022 | 6,036 | 59,917 | - | 21 | 126,756 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.27 per share. | 01 Apr 2022 | 6,036 | 65,953 | - | 13.3 | 80,098 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.97 per share. | 01 Apr 2022 | 7,621 | 67,538 | - | 6.0 | 45,497 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 01 Apr 2022 | 7,621 | 59,917 | - | 21 | 160,041 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 1,775 | 26,625 | - | - | Employee Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 168 | 113,652 | - | - | Employee Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 6,036 | 73,964 | - | - | Employee Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 7,621 | 113,820 | - | - | Employee Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 09 Mar 2022 | 2,000 | 356,345 | - | 14 | 28,000 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 09 Mar 2022 | 2,000 | 356,343 | - | 14 | 28,000 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 16 Feb 2022 | 2,000 | 358,345 | - | 14.8 | 29,664 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 16 Feb 2022 | 2,000 | 358,343 | - | 14.8 | 29,664 | Common Stock |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 48,000 | 170,712 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 14 Feb 2022 | 21,288 | 149,424 | - | 14.3 | 303,780 | Common Stock |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 16,000 | 58,467 | - | 0 | Common Stock | |
| Don Healey | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 14 Feb 2022 | 5,533 | 52,934 | - | 14.3 | 78,956 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 16,000 | 65,450 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 14 Feb 2022 | 5,533 | 59,917 | - | 14.3 | 78,956 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 16,000 | 58,436 | - | 0 | Common Stock | |
| Blake Aftab | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 14 Feb 2022 | 5,533 | 52,903 | - | 14.3 | 78,956 | Common Stock |
| Chen Schor | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.69 per share. | 28 Jan 2022 | 21,288 | 122,712 | - | 11.7 | 248,857 | Common Stock |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 48,000 | 144,000 | - | 0 | Common Stock | |
| Don Healey | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.69 per share. | 28 Jan 2022 | 5,533 | 42,467 | - | 11.7 | 64,681 | Common Stock |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 16,000 | 48,000 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 16,000 | 54,983 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.69 per share. | 28 Jan 2022 | 5,533 | 49,450 | - | 11.7 | 64,681 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.69 per share. | 28 Jan 2022 | 5,564 | 42,436 | - | 11.7 | 65,043 | Common Stock |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 16,000 | 48,000 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 295,000 | 295,000 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 16.90 per share. | 03 Jan 2022 | 2,000 | 364,345 | - | 16.9 | 33,799 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.03 per share. | 03 Jan 2022 | 4,000 | 360,343 | - | 14.0 | 56,118 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 03 Jan 2022 | 6,000 | 366,343 | - | 18.0 | 108,125 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.03 per share. | 03 Jan 2022 | 4,000 | 360,345 | - | 14.0 | 56,121 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 03 Jan 2022 | 6,000 | 366,345 | - | 18.0 | 108,131 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 03 Jan 2022 | 2,000 | 364,343 | - | 16.9 | 33,864 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 14.00 per share. | 10 Dec 2021 | 214,285 | 242,285 | - | 14 | 2,999,990 | Common Stock |
| Michael G. Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 37,000 | 37,000 | - | - | Stock Option (right to Buy) | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 80,000 | 80,000 | - | 0 | Common Stock | |
| Blake Aftab | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 60,000 | 60,000 | - | - | Stock Option (right to Buy) | |
| Chen Schor | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 240,000 | 240,000 | - | 0 | Common Stock | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 80,000 | 80,000 | - | 0 | Common Stock | |
| Francesco Galimi | SVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 80,000 | 86,983 | - | 0 | Common Stock | |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 16 Jun 2021 | 8,982 | 89,836 | - | 10.5 | 94,611 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 16 Jun 2021 | 7,484 | 74,841 | - | 10.5 | 78,832 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 11.16 per share. | 15 Jun 2021 | 1,923 | 215,883 | - | 11.2 | 21,454 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 11.16 per share. | 15 Jun 2021 | 1,924 | 215,883 | - | 11.2 | 21,465 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.97 per share. | 04 Jun 2021 | 6,983 | 6,983 | - | 6.0 | 41,689 | Common Stock |
| Francesco Galimi | SVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2021 | 6,983 | 121,441 | - | - | Employee Stock Option (Right to Buy) | |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 03 Jun 2021 | 8,982 | 98,818 | - | 12.1 | 108,279 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 03 Jun 2021 | 7,484 | 82,325 | - | 12.1 | 90,220 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.42 per share. | 19 May 2021 | 6,872 | 90,421 | - | 13.4 | 92,244 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.73 per share. | 19 May 2021 | 733 | 107,800 | - | 13.7 | 10,062 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.42 per share. | 19 May 2021 | 8,249 | 108,533 | - | 13.4 | 110,728 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.73 per share. | 19 May 2021 | 612 | 89,809 | - | 13.7 | 8,401 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.06 per share. | 18 May 2021 | 3,100 | 218,706 | - | 14.1 | 43,573 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 18 May 2021 | 900 | 217,806 | - | 14.2 | 12,805 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 18 May 2021 | 892 | 217,807 | - | 14.2 | 12,692 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 14.05 per share. | 18 May 2021 | 3,108 | 218,699 | - | 14.1 | 43,676 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 13.24 per share. | 12 May 2021 | 5,000 | 221,806 | - | 13.2 | 66,205 | Common Stock |
| Aya Jakobovits | Director | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 12 May 2021 | 5,000 | 221,807 | - | 13.2 | 66,128 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.90 per share. | 05 May 2021 | 4,426 | 100,351 | - | 13.9 | 61,502 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 14.70 per share. | 05 May 2021 | 3,670 | 116,782 | - | 14.7 | 53,951 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 13.90 per share. | 05 May 2021 | 5,312 | 120,452 | - | 13.9 | 73,814 | Common Stock |
| Chen Schor | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 14.70 per share. | 05 May 2021 | 3,058 | 97,293 | - | 14.7 | 44,954 | Common Stock |
| Carl L Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Steve Dubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Aya Jakobovits | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey A. Chodakewitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 1,172 | 1,172 | - | - | Stock Option (Right to Buy) | |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 20 Apr 2021 | 8,982 | 125,764 | - | 12.0 | 107,830 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 20 Apr 2021 | 7,484 | 104,777 | - | 12.0 | 89,846 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.04 per share. | 06 Apr 2021 | 7,484 | 112,261 | - | 13.0 | 97,584 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.04 per share. | 06 Apr 2021 | 8,982 | 134,746 | - | 13.0 | 117,116 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.30 per share. | 30 Mar 2021 | 2,984 | 124,245 | - | 12.3 | 36,703 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 30 Mar 2021 | 4,500 | 119,745 | - | 13.2 | 59,490 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 30 Mar 2021 | 5,400 | 143,728 | - | 13.2 | 71,388 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.30 per share. | 30 Mar 2021 | 3,582 | 149,128 | - | 12.3 | 44,059 | Common Stock |
| Chen Schor | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 22,985 | 0 | - | - | Common Stock | |
| Chen Schor | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 27,014 | 0 | - | - | Common Stock | |
| Chen Schor | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 19,286 | 0 | - | - | Common Stock | |
| Chen Schor | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 23,570 | 0 | - | - | Common Stock | |
| Chen Schor | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 26,070 | 0 | - | - | Common Stock | |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.66 per share. | 16 Mar 2021 | 2,089 | 127,229 | - | 15.7 | 32,714 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 16 Mar 2021 | 2,508 | 152,710 | - | 15.1 | 37,796 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.66 per share. | 16 Mar 2021 | 5,395 | 129,318 | - | 15.7 | 84,486 | Common Stock |
| Chen Schor | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 16 Mar 2021 | 6,474 | 155,218 | - | 15.1 | 97,563 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 12 Feb 2021 | 104,050 | 396,657 | - | 13 | 1,352,650 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 12 Feb 2021 | 420,299 | 5,243,259 | - | 13 | 5,463,887 | Common Stock |
| Chen Schor | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 421,600 | 421,600 | - | - | Stock Option (Right to Buy) | |
| Stewart Abbot | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 106,900 | 106,900 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 30,400 | 30,400 | - | - | Stock Option (Right to Buy) | |
| Erez Chimovits | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 12 Feb 2021 | 420,299 | 5,243,259 | - | 13 | 5,463,887 | Common Stock |
| Erez Chimovits | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 12 Feb 2021 | 104,050 | 396,657 | - | 13 | 1,352,650 | Common Stock |
| Lloyd Klickstein | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 41,100 | 41,100 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 28,400 | 28,400 | - | - | Stock Option (Right to Buy) | |
| Carrie Krehlik | Chief Human Resources Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 11,200 | 11,200 | - | - | Stock Option (Right to Buy) | |
| Lloyd Klickstein | Chief Innovation Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 26 Jan 2021 | 4,957 | 11,931 | - | 0 | Common Stock | |
| Lloyd Klickstein | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 16,888 | 16,888 | - | 0 | Common Stock | |
| Chen Schor | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Stewart Abbot | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Don Healey | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Lloyd Klickstein | Chief Innovation Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Francesco Galimi | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Carrie Krehlik | Chief Human Resources Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Bastiano Sanna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 28,828 | 28,828 | - | - | Stock Option (Right to Buy) |